PURPOSE: To assess the intracellular delivery, antiretroviral activity and cytotoxicity of poly(ε-caprolactone) (PCL) nanoparticles containing the antiretroviral drug dapivirine. METHODS: Dapivirine-loaded nanoparticles with different surface properties were produced using three surface modifiers: poloxamer 338 NF (PEO), sodium lauryl sulfate (SLS) and cetyl trimethylammonium bromide (CTAB). The ability of nanoparticles to promote intracellular drug delivery was assessed in different cell types relevant for vaginal HIV transmission/microbicide development. Also, antiretroviral activity of nanoparticles was determined in different cell models, as well as their cytotoxicity. RESULTS: Dapivirine-loaded nanoparticles were readily taken up by different cells, with particular kinetics depending on the cell type and nanoparticles, resulting in enhanced intracellular drug delivery in phagocytic cells. Different nanoparticles showed similar or improved antiviral activity compared to free drug. There was a correlation between increased antiviral activity and increased intracellular drug delivery, particularly when cell models were submitted to a single initial short-course treatment. PEO-PCL and SLS-PCL nanoparticles consistently showed higher selectivity index values than free drug, contrasting with high cytotoxicity of CTAB-PCL. CONCLUSIONS: These results provide evidence on the potential of PCL nanoparticles to affect in vitro toxicity and activity of dapivirine, depending on surface engineering. Thus, this formulation approach may be a promising strategy for the development of next generation microbicides.
PURPOSE: To assess the intracellular delivery, antiretroviral activity and cytotoxicity of poly(ε-caprolactone) (PCL) nanoparticles containing the antiretroviral drug dapivirine. METHODS:Dapivirine-loaded nanoparticles with different surface properties were produced using three surface modifiers: poloxamer 338 NF (PEO), sodium lauryl sulfate (SLS) and cetyl trimethylammonium bromide (CTAB). The ability of nanoparticles to promote intracellular drug delivery was assessed in different cell types relevant for vaginal HIV transmission/microbicide development. Also, antiretroviral activity of nanoparticles was determined in different cell models, as well as their cytotoxicity. RESULTS:Dapivirine-loaded nanoparticles were readily taken up by different cells, with particular kinetics depending on the cell type and nanoparticles, resulting in enhanced intracellular drug delivery in phagocytic cells. Different nanoparticles showed similar or improved antiviral activity compared to free drug. There was a correlation between increased antiviral activity and increased intracellular drug delivery, particularly when cell models were submitted to a single initial short-course treatment. PEO-PCL and SLS-PCL nanoparticles consistently showed higher selectivity index values than free drug, contrasting with high cytotoxicity of CTAB-PCL. CONCLUSIONS: These results provide evidence on the potential of PCL nanoparticles to affect in vitro toxicity and activity of dapivirine, depending on surface engineering. Thus, this formulation approach may be a promising strategy for the development of next generation microbicides.
Authors: Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191
Authors: A David Woolfson; R Karl Malcolm; Ryan J Morrow; Clare F Toner; Stephen D McCullagh Journal: Int J Pharm Date: 2006-06-23 Impact factor: 5.875
Authors: Yven Van Herrewege; Lieve Penne; Chris Vereecken; Katrien Fransen; Guido van der Groen; Luc Kestens; Jan Balzarini; Guido Vanham Journal: AIDS Res Hum Retroviruses Date: 2002-10-10 Impact factor: 2.205
Authors: José das Neves; Francisca Araújo; Fernanda Andrade; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento Journal: Pharm Res Date: 2014-01-22 Impact factor: 4.200
Authors: Tao Zhang; Chi Zhang; Vivek Agrahari; James B Murowchick; Nathan A Oyler; Bi-Botti C Youan Journal: Antiviral Res Date: 2012-12-26 Impact factor: 5.970
Authors: Anita Leporati; Mikhail S Novikov; Vladimir T Valuev-Elliston; Sergey P Korolev; Anastasia L Khandazhinskaya; Sergey N Kochetkov; Suresh Gupta; Julian Goding; Elijah Bolotin; Marina B Gottikh; Alexei A Bogdanov Journal: Nanomedicine Date: 2016-07-25 Impact factor: 5.307
Authors: Supriya D Mahajan; Ravikumar Aalinkeel; Wing-Cheung Law; Jessica L Reynolds; Bindukumar B Nair; Donald E Sykes; Ken-Tye Yong; Indrajit Roy; Paras N Prasad; Stanley A Schwartz Journal: Int J Nanomedicine Date: 2012-10-05
Authors: Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko Journal: J Control Release Date: 2015-08-24 Impact factor: 9.776